Alcon increases its acquisition offer for STAAR Surgical, emphasizing a final deal amid shareholder debates and delays in the ...

The study evaluated thermal dynamics associated with CW-TSCPC and TLT using MicroPulse technology, such as temperature peak, ...

Ocular Therapeutix announced it plans to accelerate its intended New Drug Application (NDA) for AXPAXLI (OTX-TKI) for the ...

Panelists discuss how aflibercept’s structural design and the higher molar dose of its 8-mg formulation enhance VEGF binding, treatment durability, and clinical predictability.

Panelists discuss how faricimab’s dual VEGF-A and Ang-2 inhibition may offer vascular stability advantages over single-pathway blockade, despite ongoing questions about Ang-2’s independent therapeutic ...

Formosa and Rxilient have an exclusive licensing agreement for APP13007 commercialization, including regulatory and sales ...

The US Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to EyeYon Medical for its US clinical study of EndoArt, which is currently designated by the FDA ...

ViaLase announced the first patient has been treated in its US-based Investigational Device Exemption (IDE) clinical trial ...

Iolyx Therapeutics and Laboratoires Théa (Théa), through support from its subsidiary Théa Open Innovation, have entered into ...

Of the 1000 patients with dry eye symptoms surveyed, 80% stated that “they would try a science-backed eye drop that mimics ...

PainReform has released details on, and the commencement of, its development plan for OcuRing-K, including an upcoming phase 2 clinical trial. 1 ...

The team reviews acoltremon’s mechanism in promoting basal tear production and maintaining ocular surface health. The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for ...